What is the survival rate for stage 4 non-small cell lung cancer? According to the American Cancer Society, the 5-year relative survival rate for stage 4 NSCLC is 9%. This survival rate is based ...
Scientists found that aggressive lung cancer cells create their own electrical network, helping them spread. This unique ...
A recent analysis shows that additional invasive staging modalities lead to relevant changes in target volume in some ...
AstraZeneca (AZ) has announced that its immunotherapy Imfinzi (durvalumab) has been approved by the European Commission (EC) ...
TAIPEI (Taiwan News) — A Taiwanese-led study published in Nature has found that small-cell lung cancer (SCLC) cells exhibit ...
IMFINZITM (durvalumab) has received approval in the European Union as a monotherapy for treating adults with limited-stage ...
As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...
Chen, F. (2025) Advances in the Application of Deep Learning in Prognostic Models for Non-Small Cell Lung Cancer. Health, 17, ...
Explore how adjuvant osimertinib aids in detecting molecular residual disease in resected EGFR-mutated NSCLC, offering ...
Johnson & Johnson announced that new data from its oncology pipeline will be presented at the 2025 European Lung Cancer Congress, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback